跳至主要内容
临床试验/ACTRN12622001055796
ACTRN12622001055796尚未招募1 期

HypErtensive Augmentation with metaraminol During acute ischaemic STroke Assisting Reperfusion Therapies

Royal Adelaide Hospital0 个研究点目标入组 25 人开始时间: 2022年7月29日最近更新:

试验速览

阶段
1 期
状态
尚未招募
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1) Acute anterior circulation ischaemic stroke with measurable neurologic deficit
  • 2) Demonstration of penumbra of CT perfusion imaging (Delay time (DT) lesion >3 seconds volume > 30 mL, as measured by MiSTAR software)
  • 3) Initial systolic blood pressure on ED presentation below 160mmHg

排除标准

  • 1) Known renal failure (eGFR < 30mL)
  • 2) Iodine contrast hypersensitivity
  • 3) Any contraindication to Metaraminol administration ((hypersensitivity to Metaraminol including sulfite allergy, nonselective Monoamine Oxidase Inhibitor (MAO-I) therapy (phenelzine, tranylcypromine) in the past 14 days))
  • 4) <50 years old
  • 5) Previous intracerebral or subarachnoid haemorrhage
  • 6) Presence of an intracranial aneurysm or arteriovenous malformation
  • 7) Presence of an aortic dissection
  • 8) Presence of an acute or recent (<30 days) myocardial infarction
  • 9) Recent (<1 month) left ventricular failure
  • 10) Any other condition which, in the opinion of the Investigator, increases the risk of blood pressure augmentation

研究者

相似试验